Prostate cancer (CaP) is the most frequently diagnosed cancer and the second cause of cancer deaths in men in the US. Four potent anti-cancer activities have been ascribed to Vitamin D: 1) anti-proliferation, 2) anti-angiogenesis, 3) pro-apoptosis and 4) pro-differentiation. However, vitamin D also mobilizes calcium stores causing toxic hypercalcemic effects. New analogs have been developed that retain the anti-cancer activities of vitamin D but without the associated systemic toxicity. Our hypothesis is that vitamin D compounds, that retain anti-cancer properties but have reduced calcemic activity, can be used as a chemopreventive agent to prevent/slow the progression and metastatic spread of CaP. We propose 4 specific aims: I: To determine if calcitriol and two vitamin D analogs with low systemic toxicity (1LX23-7553 & QW1624F2-2) can prevent/slow carcinogenesis in an autochthonous model of CaP (TRAMP) and characterize the molecular effects of these compounds during prostate cancer progression. II: To determine if calcitriol and the less calcemic vitamin D compounds ILX23-7553 & QW1624F2-2 can prevent/slow the development and metastatic spread of androgen-independent CaP in castrated TRAMP animals and characterize the molecular effects of these compounds on androgen-independent disease. III: To identify key molecular pathways involved in vitamin D?s anti-cancer activity by comparing the molecular phenotype of tumor-derived cells from naive TRAMP tumors and vitamin D-resistant TRAMP tumors. IV: To evaluate the in vivo response of human CaP to ILX23-7553 by treating men with localized CaP prior to prostatectomy with ILX23-7553 and characterizing the molecular phenotype of the response. Effects of calcitriol, ILX23-7553 and QWI1624F2-2 treatment on proliferation, apoptosis, angiogenesis and differentiation will be studied in androgen-dependent and -independent CaP. Vitamin D resistant tumors will be induced in TRAMP and the molecular phenotype compared to naive TRAMP tumors. Finally a clinical trial examining the in vivo molecular response of organ confined human CaP to ILX23-7553 is proposed. These studies will provide preclinical data on the preventive activity of vitamin D compounds that can be used to design and initiate clinical trials using these compounds as a chemopreventive agent for human prostate cancer. These studies will identify key molecular pathways for vitamin D action that can be used to identify patients that are most/least likely to benefit from vitamin D therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Kim, Young Shin
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Battaglia, Sebastiano; Karasik, Ellen; Gillard, Bryan et al. (2017) LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer. Clin Epigenetics 9:82
Sabnis, Neha G; Miller, Austin; Titus, Mark A et al. (2017) The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Mol Cancer Res 15:128-140
Seedhouse, Steven J; Affronti, Hayley C; Karasik, Ellen et al. (2016) Metastatic phenotype in CWR22 prostate cancer xenograft following castration. Prostate 76:359-68
Gangavarapu, Kalyan J; Miller, Austin; Huss, Wendy J (2016) Gene Expression in Single Cells Isolated from the CWR-R1 Prostate Cancer Cell Line and Human Prostate Tissue Based on the Side Population Phenotype. Single Cell Biol 5:
Doig, Craig L; Battaglia, Sebastiano; Khanim, Farhat L et al. (2016) Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol 155:47-55
Long, Mark D; Sucheston-Campbell, Lara E; Campbell, Moray J (2015) Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol 230:758-66
Thorne, James L; Campbell, Moray J (2015) Nuclear receptors and the Warburg effect in cancer. Int J Cancer 137:1519-27
Singh, Prashant K; Long, Mark D; Battaglia, Sebastiano et al. (2015) VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription. Epigenetics 10:40-9
Long, Mark D; Campbell, Moray J (2015) Pan-cancer analyses of the nuclear receptor superfamily. Nucl Receptor Res 2:
Long, Mark D; van den Berg, Patrick R; Russell, James L et al. (2015) Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. Nucleic Acids Res 43:7330-48

Showing the most recent 10 out of 26 publications